Evidence map›Paper›PMID 38135952›Full record

ArticleBioengineering (Basel, Switzerland)2023

Synthesis, Characterization, DFT, and In Silico Investigation of Two Newly Synthesized β-Diketone Derivatives as Potent COX-2 Inhibitors.

Malahat Musrat Kurbanova, Abel Mammadali Maharramov, Arzu Zabit Sadigova, Fidan Zaur Gurbanova, Suraj Narayan Mali, Rashad Al-Salahi, Youness El Bakri, Chin-Hung Lai

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Malahat Musrat KurbanovaOrganic Chemistry Department, Baku State University, Z. Khalilov 23, Baku 1148, Azerbaijan.ORCID 0000-0001-9857-9505
Abel Mammadali MaharramovOrganic Chemistry Department, Baku State University, Z. Khalilov 23, Baku 1148, Azerbaijan.
Arzu Zabit SadigovaOrganic Chemistry Department, Baku State University, Z. Khalilov 23, Baku 1148, Azerbaijan.
Fidan Zaur GurbanovaDepartment of Pharmacy and Biotechnology, Bioinformatics, University of Bologna, Via Marsala, 49/A, 40126 Bologna, Italy.
Suraj Narayan MaliDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra 835215, India.ORCID 0000-0003-1995-136X
Rashad Al-SalahiDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0003-1747-2736
Youness El BakriDepartment of Theoretical and Applied Chemistry, South Ural State University, Lenin Prospect 76, Chelyabinsk 454080, Russia.ORCID 0000-0002-5759-6568
Chin-Hung LaiDepartment of Medical Applied Chemistry, Chung Shan Medical University, Taichung 40241, Taiwan.ORCID 0000-0002-2768-7098

Funding

King Saud University RSP-2023R353
6 · The paper itself

Abstract

Despite extensive genetic and biochemical characterization, the molecular genetic basis underlying the biosynthesis of β-diketones remains largely unexplored. β-Diketones and their complexes find broad applications as biologically active compounds. In this study, in silico molecular docking results revealed that two β-diketone derivatives, namely 2-(2-(4-fluorophenyl)hydrazono)-5,5-dimethylcyclohexane-1,3-dione and 5,5-dimethyl-2-(2-(2-(trifluoromethyl)phenyl)hydrazono)cyclohexane-1,3-dione, exhibit anti-COX-2 activities. However, recent docking results indicated that the relative anti-COX-2 activity of these two studied β-diketones was influenced by the employed docking programs. For improved design of COX-2 inhibitors from β-diketones, we conducted molecular dynamics simulations, density functional theory (DFT) calculations, Hirshfeld surface analysis, energy framework, and ADMET studies. The goal was to understand the interaction mechanisms and evaluate the inhibitory characteristics. The results indicate that 5,5-dimethyl-2-(2-(2-(trifluoromethyl)phenyl)hydrazono)cyclohexane-1,3-dione shows greater anti-COX-2 activity compared to 2-(2-(4-fluorophenyl)hydrazono)-5,5-dimethylcyclohexane-1,3-dione.

Indexed as

ADMECOX-2DFTHirshfeld surfaceβ-diketone

Identifiers

PMID38135952
PMCPMC10741009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.